Materials and Methods
Clinical study. N=14 volunteers (10 men, 4 women) aged between 22 y and 34 y (mean ± SD: 25.8 ± 3.2 y) with a body mass index (BMI) of 25.7 ± 3.2 kg/m 2 completed the study. The participants were randomized to either the simulated day shift condition (7 participants) or the simulated night shift condition (7 participants); see Fig. S1 . There was a small age difference between the two groups (day shift condition: 24.0 ± 2.2 y; night shift condition: 27.6 ± 3.2 y; t 12 =2.4, p=0.031). The groups were not significantly different with regard to BMI (day shift condition: 25.9 ± 3.4 kg/m 2 ; night shift condition: 25.6 ± 3.3 kg/m 2 ; t 12 =0.14, p=0.89) or sex distribution (day shift condition: 4 men; night shift condition: 6 men; χ 1 2 
=1.4, p=0.24).
Participants were screened to be physically and psychologically healthy with no medical or drug treatment, as verified by physical examination, blood chemistry, urinalysis, and questionnaires. They reported good habitual sleep, between 6 and 10 hours in duration and habitually getting up between 06:00 and 09:00, and were no extreme morning-or evening-types as assessed by questionnaire (Composite Scale of Morningness). They showed no evidence of any sleep or circadian disorders as assessed by nocturnal polysomnography (1) and validated questionnaires (Pittsburgh Sleep Quality Index, Sleep Disorders Questionnaire, Epworth Sleepiness Scale). They had no history of drug or alcohol abuse, were free of traces of alcohol and drugs as assessed by drug screen and breathalyzer, and did not smoke. They were not involved in shift work within three months of entering the study, and did not travel across time zones within one month of entering the study. Women were not pregnant as assessed by blood-based assay.
Participants maintained a regular sleep/wake schedule in the week prior to the in-laboratory experiment, with bedtimes and wake times within 30 minutes from their self-reported habitual schedule. This was confirmed by means of wrist actigraphy, sleep diary, and participants calling a time-stamped voice mail recorder upon waking and before going to bed. In the week prior to the study, participants were requested to abstain from alcohol and caffeine.
Targeted metabolomics analysis. Although targeted metabolomics does not provide a complete assessment of the entire metabolome, it covers important metabolite classes, and the results obtained are quantifiable and highly reproducible across laboratories (2) . Targeted metabolomics is also well suited for high throughput of large number of samples as generated by time-series circadian studies.
Metabolites were quantified in the plasma samples collected at 3-h intervals during the 24-h constant routine using the AbsoluteIDQ p180 targeted metabolomics kit (Biocrates Life Sciences AG, Innsbruck, Austria) and a Waters Xevo TQ-S mass spectrometer coupled to an Acquity UPLC system (Waters Corporation, Milford, MA, USA). Plasma samples (10 μl) were prepared according to the manufacturer's instructions adding several stable isotope-labeled standards to the samples prior to the derivatization and extraction steps. Using LC/MS (liquid chromatography/mass spectrometry), 184 metabolites from 5 different compound classes (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and sphingolipids) were quantified.
The samples were run on 2×96-well plates. Sample order was randomized and three levels of quality control (QC) were run on each plate. Data were normalized between the plates using the PER3 expression. PER3 transcript levels were measured in the plasma samples collected at 3-h intervals during the 24-h constant routine using nCounter multiplexed assay (NanoString Technologies, Seattle, WA, USA). RNA was measured directly with no amplification or other enzymatic processing. 100 ng of total RNA was used for the assay. Analysis was performed using nSolver 3.0 software (NanoString Technologies, Seattle, WA, USA). Genes with an expectancy of less than 10 counts with 90% occurrence or more were removed. Background values were subtracted and data were normalized with overall geometric mean of internal control genes.
Statistical analysis.
Cosinor analysis to investigate 24-h rhythmicity in all of the metabolites, cortisol, and PER3 expression, was performed across all participants in both conditions using linear mixed-effects regression (3). Regression coefficients for mesor (center level), acrophase (timing of peak), and amplitude (difference between mesor and level at acrophase) were assessed (Table S1 ) and used for statistical testing. Rhythm significance in each of the two conditions was determined by testing amplitude against zero using t test, with a one-sided type I error threshold of 0.05. 95% confidence intervals for acrophase were computed using the delta method. Differences between conditions in acrophase, amplitude and mesor were evaluated using t test, with a two-sided type I error threshold of 0.05.
The cosinor analyses for metabolites were repeated after removal of data from the first 3 h of the 24-h constant routine period, in order to verify robustness to any transient effects from physiological adjustment to the constant routine procedures. This resulted in minor differences in acrophase estimates (mean ± SD: 38 ± 34 min) and did not substantively affect any of the findings. Separately, the cosinor analyses for metabolites were repeated with time awake added as a regression term. Out of the 132 metabolites analyzed, 115 did not show a significant effect of time awake. For the 17 metabolites that did show a significant effect of time awake, the levels of 7 metabolites decreased and the levels of 10 metabolites increased across the 24-h constant routine. In all cases, the total change over time was small relative to the 24-h overall average. The constant routine procedure and the increasing sleep pressure associated with 24-h sustained wakefulness did not produce any substantive confounds in the metabolites' temporal profiles.
The timing of dim light melatonin onset (DLMO) was analyzed with non-linear mixed-effects regression of a Taylor series approximation of the melatonin curve (Fig. S2) . Differences between conditions were evaluated using t test. Differences between baseline and constant routine were evaluated using paired-sample t test. Although this methodology does not require the definition of a threshold to estimate timing differences, we used a conventional 10 pg/ml threshold (4) to define the DLMO.
Principal component analysis (PCA) was based on scree plot to determine how many factors to retain, and used varimax rotation to assess factor loadings. All statistical analyses were implemented in SAS version 9.4.
Pathway analyses were performed for the day shift and night shift conditions separately (Tables  S3, S4 ) using the MetaboAnalyst 3.0 database (5). Enriched pathways were identified using a false discovery rate (FDR) threshold of 0.05. . Plasma melatonin and dim light melatonin onset (DLMO) at baseline and during the constant routine (CR) after simulated day shift work (left) and night shift work (right). For the day shift condition, the threshold of 10 pg/ml was crossed during baseline at 21:47 (± 41 min) and during the constant routine at 21:22 (± 30 min) -indicating a phase difference (advance) of -25 min (± 37 min), which was not statistically significant (t 6 =-0.66, p=0.53). For the night shift condition, the threshold was crossed during baseline at 20:58 (± 37 min) and during the constant routine at 22:50 (± 34 min) -indicating a phase difference (delay) of 112 min (± 32 min), which was statistically significant (t 6 =3.53, p=0.012). There was no significant difference in the baseline phase of the DLMO between the two groups (t 12 =-1.23, p=0.24); but during the constant routine, the timing of the DLMO was significantly later by 88 min (± 32 min) in the night shift condition (t 12 =2.72, p=0.019). Gray/black: baseline. Orange/red: constant routine after simulated day shift condition. Purple/blue: constant routine after simulated night shift condition. Light tinted circles: group means (± SE). Dark tinted curves: Taylor series approximation fits. Dashed line: 10 pg/ml threshold for DLMO. Diamonds: timing of DLMO (± SE). Fig. S4 . Transcript levels of PER3 gene expression during constant routine after simulated day shift work (orange) and night shift work (purple), plotted against time of day (top) and against circadian time relative to DLMO (bottom). For the day shift condition, there was a significant 24-h rhythm (t 6 =3.14, p=0.010), and the acrophase occurred at 01:30 (± 73 min). For the night shift condition, there was also a significant 24-h rhythm (t 6 =3.93, p=0.004), and the acrophase occurred at 04:11 (± 60 min). The phase difference between the two groups during the constant routine involved a delay of 160 min (± 76 min) in the night shift condition, which was not statistically significant (t 12 =1.70, p=0.12) but was similar to the delay of 100 min (± 67 min) in the circadian rhythm of plasma cortisol (see Fig. S3 ). Orange/red: constant routine after simulated day shift condition. Purple/blue: constant routine after simulated night shift condition. Circles: group means (± SE). Curves: cosinor fits. Red and blue markers: timing of acrophase (and 95% confidence interval). (Table S2 ). D = day shift condition; N = night shift condition. 03 = 00:00-06:00; 09 = 06:00-12:00; 15 = 12:00-18:00; 21 = 18:00-24:00.
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